Comparative Pharmacology
Head-to-head clinical analysis: NAPRELAN versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPRELAN versus NAPROSYN.
NAPRELAN vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
750 mg to 1000 mg orally once daily, with or without food.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category C
Category C
NSAID
NSAID